Company profile
Gentle Health
A cash-pay weight-management telehealth service advertising compounded oral semaglutide, injectable semaglutide and injectable tirzepatide, with physician review and pharmacy shipment. Its public terms describe a recurring monthly subscription with cancellation before pharmacy submission or beginning 30 days after the order date once submitted.
- Operating status
- Operating
- Updated
Facts were checked against the primary sources listed on this page as of the date shown. This profile reports publicly documented facts; it makes no clinical claims and does not rate clinical quality or recommend treatment. How we research
On this page
What Gentle Health does
Gentle Health markets online weight-management consultations and pharmacy-shipped compounded GLP-1 medication: oral semaglutide, injectable semaglutide and injectable tirzepatide, the last a dual GIP/GLP-1. The site says its cash-pay prices include doctor reviews and dose decisions, messaging and video visits, medication and refrigerated delivery. Insurance is not accepted; the homepage says HSA and FSA cards are.
The terms describe Gentle Health as a platform connecting patients with licensed doctors, not a pharmacy or drug manufacturer. A prescription requires a doctor’s decision. FDA distinguishes compounded drugs from approved generic drugs: compounded products are not FDA-approved. Listing the advertised products here is not an assessment of their clinical performance or of a particular prescription’s legal eligibility for compounding.
History, identity and clinical organization
Gentle Health supplied 2026 as its founding year and described itself as a small, online-only company in information provided to Inside Telehealth on September 10, 2026. No headquarters location was supplied.
The company’s coverage account, first published in August 2026, says it began serving Arkansas and Kentucky before expanding to 40 states plus DC. It names Missouri as the newest addition on September 18. Its Missouri page, which returned 404 when we checked on September 18, now loads and lists Dr. Simmons’s Missouri license with a link to the state medical board. The history article does not establish the company’s incorporation or launch date. We have not verified a registered operating entity, ownership percentages or funding history from the public documents reviewed.
Its physician biography names James Simmons, MD, as medical director from 2026 and links professional identifiers and state-license records. The coverage account says he personally evaluates and treats every patient, with individual state licenses obtained through the Interstate Medical Licensure Compact, and includes Missouri in that footprint.
A separate company article about its chat service says founders answer public-site questions when available. It distinguishes customer support from clinical care.
How access works
Gentle Health’s state-workflow explanation describes two starting paths: an online intake reviewed asynchronously, or an intake followed by a scheduled video visit. The assigned path depends on the patient’s location. The clinician can request more information or a video visit even when the process begins asynchronously, and may decline to prescribe.
These are the company’s stated operating procedures, not our interpretation of what each state’s law requires. We did not submit an intake, purchase treatment or test appointment access. The terms restrict the service to adults aged 18 or older and exclude urgent and emergency care.
Advertised prices and billing commitments
The following are the homepage’s advertised monthly prices, observed September 26, 2026 and unchanged since September 18. Tier names are the company’s pricing labels, not recommendations about which product or tier a patient should use.
| Advertised compounded product | Starting tier / month | Medium tier / month | High tier / month |
|---|---|---|---|
| Oral semaglutide | $112 | $189 | $258 |
| Injectable semaglutide | $135 | $159 | $199 |
| Injectable tirzepatide | $169 | $219 | $269 |
The terms, dated September 24, 2026, say initial intake and consultation are free and the first medication request starts a recurring monthly subscription. An order and subscription may be canceled before the order is sent to the pharmacy. Once submitted, the subscription may be canceled beginning 30 days after the order date. Cancellation takes effect immediately and stops future billing, but the remainder of the current billing month is not refunded. Refund requests after pharmacy submission are considered case by case.
Privacy and evidence limits
The privacy notice, effective September 24, 2026, describes uses of health information for treatment, payment (through the payment processor Stripe) and healthcare operations, and patient record-access and amendment rights. It also identifies analytics and advertising tools on public marketing and blog pages, while stating those tools do not run in intake, account or doctor pages. That separation is the company’s published policy; we have not audited network traffic, security controls or actual data handling.
This is a public-document profile, not a patient-experience test. Coverage, pricing, clinical staffing and fulfillment descriptions can vary over time. We have not verified pharmacy operations or inferred headquarters from a street address embedded in website metadata.
Gentle Health medication prices
Published monthly pricing and cost components for Gentle Health's named medication programs, from the national medication guides. These are advertised prices, not a quote; availability in a particular state is shown in the state guides. Each product is labelled as one of three presentations: an advertised monthly bundle, a known monthly subtotal (not a final bill), or a record where dose-level totals are not disclosed, which may give only a starting figure or cost components such as a membership.
Compounded oral semaglutide · oral
Advertised monthly bundle
- 2–4 mg/day
- $112/mo
- >4–8 mg/day
- $189/mo
- >8–12 mg/day
- $258/mo
Medication, unlimited text and video visits with the doctor, and delivery; the page says the price is the whole price, with no membership fees, shipping fees or added taxes. The page describes these as once-daily drops under the tongue, not Wegovy tablets.
Not priced: Patient-specific laboratory testing is not priced on the reviewed page.
Billing and introductory offers
Monthly price by prescribed dose tier, billed monthly. The order and subscription can be canceled before the order is sent to the pharmacy; once sent, the subscription can be canceled 30 days after the order date, and charges already made, including the current month's, are not prorated or refunded.
Price check: . Gentle Health — services, price table and frequently asked questions
Compounded injectable semaglutide · injection
Advertised monthly bundle
- 0.24–0.48 mg/wk
- $135/mo
- >0.48–1.2 mg/wk
- $159/mo
- >1.2–2.4 mg/wk
- $199/mo
Medication, unlimited text and video visits with the doctor, and delivery; the page says the price is the whole price, with no membership fees, shipping fees or added taxes.
Not priced: Patient-specific laboratory testing is not priced on the reviewed page.
Billing and introductory offers
Monthly price by prescribed dose tier, billed monthly. The order and subscription can be canceled before the order is sent to the pharmacy; once sent, the subscription can be canceled 30 days after the order date, and charges already made, including the current month's, are not prorated or refunded.
Price check: . Gentle Health — services, price table and frequently asked questions
Compounded injectable tirzepatide · injection
Advertised monthly bundle
- 2.5–5 mg/wk
- $169/mo
- >5–10 mg/wk
- $219/mo
- >10–15 mg/wk
- $269/mo
Medication, unlimited text and video visits with the doctor, and delivery; the page says the price is the whole price, with no membership fees, shipping fees or added taxes.
Not priced: Patient-specific laboratory testing is not priced on the reviewed page.
Billing and introductory offers
Monthly price by prescribed dose tier, billed monthly. The order and subscription can be canceled before the order is sent to the pharmacy; once sent, the subscription can be canceled 30 days after the order date, and charges already made, including the current month's, are not prorated or refunded.
Price check: . Gentle Health — services, price table and frequently asked questions
Full details: GLP-1 medication access guide · Semaglutide guide · Tirzepatide guide · Official site ↗
Across the directory
Explore Gentle Health across Inside Telehealth
These links point to currently published guides that include Gentle Health. They organize existing evidence; they do not add a recommendation or establish that every service is available everywhere.
Care-area guides
Medication-access guides
State directories
Browse 40 state directories
- Alabama
- Arizona
- Arkansas
- Colorado
- Connecticut
- Delaware
- Florida
- Georgia
- Hawaii
- Idaho
- Illinois
- Indiana
- Iowa
- Kansas
- Kentucky
- Louisiana
- Maine
- Maryland
- Michigan
- Minnesota
- Mississippi
- Missouri
- Montana
- Nebraska
- Nevada
- New Hampshire
- New Jersey
- North Carolina
- North Dakota
- Ohio
- Oklahoma
- Pennsylvania
- South Dakota
- Tennessee
- Utah
- Vermont
- Washington
- West Virginia
- Wisconsin
- Wyoming
Availability claims
One row per jurisdiction and reported status. Scopes that share a status, attribution, source and observation date are listed together in a single row; a scope the company reports differently keeps its own row. "Company / platform" means the company as a whole, not every service. "Company-reported" means the company said it; it has not been independently checked unless the attribution says so. Read each row's note.
| Jurisdiction | Scope | Status | Attribution | Observed | Source |
|---|---|---|---|---|---|
| Alabama (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Alabama. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Alabama. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Alabama. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Arizona (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Arizona. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Arizona. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Arizona. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Arkansas (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Arkansas. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Arkansas. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Arkansas. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Colorado (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Colorado. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Colorado. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Colorado. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Connecticut (US) |
| Available | Company-reported | Gentle Health — Connecticut GLP-1 weight-loss service page, Gentle Health | |
Weight care: The company advertises statewide Connecticut delivery for its compounded oral semaglutide, injectable semaglutide and injectable tirzepatide weight-care programs. This is company-advertised access, not independently verified fulfillment, stock, individual eligibility or a prescription guarantee. Compounded injectable semaglutide: The company's Connecticut page advertises compounded injectable semaglutide with statewide delivery. This is an advertised compounded product, not a branded medicine or FDA-approved generic. Pharmacy fulfillment, stock, clinician approval and individual eligibility remain unverified. Compounded injectable tirzepatide: The company's Connecticut page advertises compounded injectable tirzepatide with statewide delivery. This is an advertised compounded product, not branded Zepbound or Mounjaro or an FDA-approved generic. Pharmacy fulfillment, stock, clinician approval and individual eligibility remain unverified. Compounded oral semaglutide: The company's Connecticut page advertises compounded oral semaglutide with statewide delivery. This is an advertised compounded product, not a branded medicine or FDA-approved generic. Pharmacy fulfillment, stock, clinician approval and individual eligibility remain unverified. | |||||
| Delaware (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Delaware. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Delaware. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Delaware. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| District of Columbia (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including District of Columbia. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including District of Columbia. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including District of Columbia. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Florida (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Florida. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Florida. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Florida. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Georgia (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Georgia. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Georgia. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Georgia. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Hawaii (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Hawaii. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Hawaii. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Hawaii. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Idaho (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Idaho. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Idaho. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Idaho. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Illinois (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Illinois. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Illinois. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Illinois. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Indiana (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Indiana. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Indiana. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Indiana. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Iowa (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Iowa. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Iowa. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Iowa. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Kansas (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Kansas. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Kansas. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Kansas. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Kentucky (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Kentucky. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Kentucky. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Kentucky. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Louisiana (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Louisiana. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Louisiana. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Louisiana. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Maine (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Maine. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Maine. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Maine. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Maryland (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Maryland. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Maryland. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Maryland. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Michigan (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Michigan. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Michigan. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Michigan. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Minnesota (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Minnesota. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Minnesota. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Minnesota. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Mississippi (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Mississippi. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Mississippi. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Mississippi. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Missouri (US) |
| Available | Company-reported | Gentle Health — Missouri GLP-1 weight-loss service page, Gentle Health | |
Weight care: Gentle Health's Missouri page was live when rechecked September 26 and advertises its compounded oral semaglutide, injectable semaglutide and injectable tirzepatide weight-care programs; the coverage article says Missouri was added September 18. This is company-reported access, not independently verified fulfillment, stock, individual eligibility or a prescription guarantee. Compounded injectable semaglutide: Gentle Health's Missouri page was live when rechecked September 26 and advertises compounded injectable semaglutide for Missouri; the coverage article says Missouri was added September 18. This is an advertised compounded product, not a branded medicine or FDA-approved generic. Pharmacy fulfillment, stock, clinician approval and individual eligibility remain unverified. Compounded injectable tirzepatide: Gentle Health's Missouri page was live when rechecked September 26 and advertises compounded injectable tirzepatide for Missouri; the coverage article says Missouri was added September 18. This is an advertised compounded product, not branded Zepbound or Mounjaro or an FDA-approved generic. Pharmacy fulfillment, stock, clinician approval and individual eligibility remain unverified. Compounded oral semaglutide: Gentle Health's Missouri page was live when rechecked September 26 and advertises compounded oral semaglutide for Missouri; the coverage article says Missouri was added September 18. This is an advertised compounded product, not a branded medicine or FDA-approved generic. Pharmacy fulfillment, stock, clinician approval and individual eligibility remain unverified. | |||||
| Montana (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Montana. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Montana. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Montana. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Nebraska (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Nebraska. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Nebraska. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Nebraska. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Nevada (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Nevada. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Nevada. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Nevada. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| New Hampshire (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including New Hampshire. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including New Hampshire. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including New Hampshire. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| New Jersey (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including New Jersey. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including New Jersey. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including New Jersey. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| North Carolina (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including North Carolina. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including North Carolina. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including North Carolina. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| North Dakota (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including North Dakota. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including North Dakota. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including North Dakota. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Ohio (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Ohio. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Ohio. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Ohio. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Oklahoma (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Oklahoma. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Oklahoma. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Oklahoma. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Pennsylvania (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Pennsylvania. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Pennsylvania. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Pennsylvania. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| South Dakota (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including South Dakota. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including South Dakota. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including South Dakota. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Tennessee (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Tennessee. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Tennessee. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Tennessee. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| United States | Company / platform | Limited | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
| Utah (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Utah. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Utah. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Utah. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Vermont (US) |
| Available | Company-reported | Gentle Health — Vermont GLP-1 weight-loss service page, Gentle Health | |
Weight care: The company advertises statewide Vermont delivery for its compounded oral semaglutide, injectable semaglutide and injectable tirzepatide weight-care programs. This is company-advertised access, not independently verified fulfillment, stock, individual eligibility or a prescription guarantee. Compounded injectable semaglutide: The company's Vermont page advertises compounded injectable semaglutide with statewide delivery. This is an advertised compounded product, not a branded medicine or FDA-approved generic. Pharmacy fulfillment, stock, clinician approval and individual eligibility remain unverified. Compounded injectable tirzepatide: The company's Vermont page advertises compounded injectable tirzepatide with statewide delivery. This is an advertised compounded product, not branded Zepbound or Mounjaro or an FDA-approved generic. Pharmacy fulfillment, stock, clinician approval and individual eligibility remain unverified. Compounded oral semaglutide: The company's Vermont page advertises compounded oral semaglutide with statewide delivery. This is an advertised compounded product, not a branded medicine or FDA-approved generic. Pharmacy fulfillment, stock, clinician approval and individual eligibility remain unverified. | |||||
| Washington (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Washington. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Washington. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Washington. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| West Virginia (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including West Virginia. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including West Virginia. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including West Virginia. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Wisconsin (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Wisconsin. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Wisconsin. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Wisconsin. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
| Wyoming (US) |
| Available | Company-reported | Gentle Health — states served and expansion account, Gentle Health | |
Weight care: The company enumerates this jurisdiction in its coverage article and explicitly describes the same three compounded programs for the listed footprint: oral semaglutide, injectable semaglutide and injectable tirzepatide. This is company-advertised program access, not independently verified clinician or pharmacy licensing, a booked appointment, stock, individual prescription eligibility or legal clearance for an order. Compounded injectable semaglutide: The company names compounded injectable semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Wyoming. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded injectable tirzepatide: The company names compounded injectable tirzepatide in the program description for every jurisdiction enumerated on its coverage page, including Wyoming. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. Compounded oral semaglutide: The company names compounded oral semaglutide in the program description for every jurisdiction enumerated on its coverage page, including Wyoming. This is an advertised compounded product, not a branded or FDA-approved generic offer. The statement does not independently verify pharmacy dispensing eligibility, current stock, clinician approval, individual eligibility or legal clearance for an order. | |||||
Sources
Consolidated bibliography for this profile: every record cited in the text or behind its structured data, listed once.
- Gentle Health — services, price table and frequently asked questions — Gentle Health; Company document; accessed — Company marketing page. Prices are monthly tier labels; current cancellation language requires reading alongside the terms. No patient purchase or fulfillment test.
- Gentle Health — Terms of Service — Gentle Health; Company document; accessed — Platform role, adult eligibility, subscription trigger and current cancellation/refund terms. The terms allow cancellation before pharmacy submission or beginning 30 days after the order date once submitted; cancellation stops future billing immediately without refunding the current billing month's remainder. Reviewed text does not identify a registered operating entity.
- Gentle Health — Notice of Privacy Practices (effective September 24, 2026) — Gentle Health; Company document; accessed — Published policy, not a technical compliance audit. Describes health-information handling and separates public-site analytics from clinical/account pages. Re-read September 26, 2026: the notice is dated effective September 24, 2026 (earlier checks saw a June 2026 version); it names Stripe as payment processor and keeps analytics to public marketing and blog pages.
- Gentle Health — James Simmons, MD, clinician biography — Gentle Health; Company document; accessed — Company-reported medical-director role beginning in 2026. Linked credential records are not an independently completed all-state license audit; the role does not establish business ownership or a founding date.
- Gentle Health — states served and expansion account — Gentle Health; Company document; Published ; accessed — A subsequently updated company article, not a historical snapshot of its original publication day. Direct retrieval at 18:57 CDT on September 18 found the article body and state list describing 40 states plus Washington, DC, naming Missouri as the newest addition that day, and saying its Missouri page was being added. At that same retrieval, the linked Missouri page returned 404. Its brief cancellation summary should be read with the September 2026 terms. Re-read September 26, 2026: still 40 states plus DC with Missouri the newest (added September 18); the Missouri page now loads (see gentle-health-missouri).
- Gentle Health — Connecticut GLP-1 weight-loss service page — Gentle Health; Company document; accessed — Company landing page advertising statewide Connecticut delivery for compounded oral semaglutide, injectable semaglutide and injectable tirzepatide programs. Names James Simmons, MD and Connecticut license 086482; describes online intake with a video visit if the physician decides one is needed. Company-reported access, not an independent fulfillment test.
- Gentle Health — Vermont GLP-1 weight-loss service page — Gentle Health; Company document; accessed — Company landing page advertising statewide Vermont delivery for compounded oral semaglutide, injectable semaglutide and injectable tirzepatide programs. Names James Simmons, MD and Vermont license 042.0040663-COMP; describes online intake with a video visit if the physician decides one is needed. Company-reported access, not an independent fulfillment test.
- Gentle Health — Missouri GLP-1 weight-loss service page — Gentle Health; Company document; accessed — Company landing page for Missouri, live when checked September 26, 2026 (it returned 404 at the September 18 check). Advertises compounded oral and injectable semaglutide and injectable tirzepatide, an async-first intake with a video visit if the doctor asks for one, and names James Simmons, MD with a Missouri license and a link to the state board's verification. Says its law and coverage answers were checked on September 18, 2026. Company-reported access, not an independent fulfillment test.
- How Gentle Health's Initial Prescribing Process Varies by State — Gentle Health; Company document; Published ; accessed — Describes company procedures for asynchronous and scheduled-video review. Not independent verification of state law, appointment availability or prescribing decisions.
- A Direct Line to the People Behind Gentle Health — Gentle Health; Company document; Published ; accessed — Company description of founder participation in public chat. Customer support is distinguished from clinical care.
- FDA to Telehealth Companies: What to Know When Promoting Compounded Drugs — U.S. Food and Drug Administration; Regulator document; accessed — General explanation of compounded-product marketing and the distinction from approved generic drugs. Company-specific regulatory actions are separate records.